Wire · opportunities
Iza-bren 2.5 mg/kg dose advances to Phase 3 in EGFR-mutated NSCLC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 September 2026 · Fusion42 review
Iza-bren at a 2.5 mg/kg dose has advanced to Phase 3 trials for patients with EGFR-mutated non-small cell lung cancer (NSCLC) following progression on third-generation EGFR inhibitors. This advancement follows positive global Phase 1 data showing manageable safety and efficacy in a diverse patient population, supporting its registrational study IZABRIGHT-Lung01.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a clearer pathway to market for drugs targeting EGFR-mutated NSCLC after third-gen inhibitor failure; the confirmation of dose and global patient data now open the gate for first-in-class approvals and competition in a growing treatment gap.
◆ Coverage
1 source · 13 Sep 2026
◆ Related on Wire
◆ Topics